Search
Mipomersen
go.drugbank.com/drugs/DB05528ApprovedIt is marketed under the brand name Kynamro in the United States, and the FDA label includes a black box warning of hepatoxicity.
Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaIcatibant
go.drugbank.com/drugs/DB06196ApprovedInvestigational[A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema. … [L49776,L49781] The FDA approval was based on positive results obtained from 3 double-blind, randomized, controlled clinical trials known as FAST 1, 2, and 3, where a median time to almost complete symptom
Categories: Analgesics, Non-NarcoticEnzacamene
go.drugbank.com/drugs/DB11219ApprovedWhile its effects on the human reproductive system as an endocrine disruptor are being investigated, its use in over-the-counter and cosmetic products is approved by Health Canada.
Aluminum hydroxide
go.drugbank.com/drugs/DB06723ApprovedInvestigationalAluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate...
Mixtures: VON GEL TABLETASSutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigational[A245159,L40114] In approximately 90% of cases, patients develop immunoglobulin M (IgM) autoantibodies towards the I antigen on erythrocytes - these antibodies react optimally at 4°C and are therefore … In addition to non-pharmacological strategies, such as counseling patients to keep warm and the use of red blood cell transfusions, approximately 70% of patients require pharmacological treatment.
Nandrolone decanoate
go.drugbank.com/drugs/DB08804ApprovedIllicitInvestigational[A233849] Nandrolone decanoate was granted FDA approval on 5 October 1962.[L32564]
Categories: Bone Density Conservation AgentsOxaliplatin
go.drugbank.com/drugs/DB00526ApprovedInvestigational[A797] Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. … [A797] Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin®.[L47316]
Products: O-PLAT 50 MG POLVO LIOFILIZADO PARA INYECC IONZidebactam
go.drugbank.com/drugs/DB13090Approved[L63932] Wockhardt announced FDA approval of the cefepime-zidebactam combination on May 30, 2026, for adults with complicated urinary tract infections, including pyelonephritis, caused by designated … penicillin-binding proteins at once produces bacterial killing that persists even against organisms whose beta-lactamases zidebactam does not inhibit, including metallo-beta-lactamase producers, and against non-enzymatic
Pralatrexate
go.drugbank.com/drugs/DB06813ApprovedInvestigational[A246703] Pralatrexate was approved by the FDA on September 24, 2009. … [L37674] It is also being studied for other types of lymphoma and solid malignancy such as non-small-cell lung cancer, breast cancer, and bladder cancer.[A246678]
Meropenem
go.drugbank.com/drugs/DB00760ApprovedInvestigationalMeropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall ...